Hans-Peter Hartung

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations

Rheumatology, Relapsing-remitting Multiple Sclerosis, Immunology +8

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair Coles, Cary Twyman, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations · Full text

Immunology, Clinical Trials, Neurological Progress +4

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

Giancarlo Comi, Massimo Filippi, Frederik Barkhof et al. · The Lancet · 2001 · 1.1K citations

Autoimmune Disease, Neurological Disorder, Immunology +9

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

Paul O’Connor, Massimo Filippi, Barry G.W. Arnason et al. · The Lancet Neurology · 2009 · 402 citations · Full text

Relapsing-remitting Multiple Sclerosis, Neurological Disorder, Multicentre Study +8

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8